33 Californie, a Lyon, France-based funding fund specialised within the healthcare sector, launched their second funding fund, CaLySeed.
The purpose of this new initiative is to finance improvements in human well being, together with therapeutics, medical units, in vitro diagnostics, e-health, know-how platforms and nutraceuticals.
CaLySeed will spend money on fairness — following French public funding and enterprise growth initiatives — to assist new firms discover very important seed capital. The corporate will act as a monetary and strategic associate for entrepreneurs and progressive startups, supporting them of their early phases, from the preliminary proof of idea by to finalizing their first fundraising.
Led by President Stéphane Legastelois and Elodie Panier, CaLySeed will focus totally on investments in Auvergne Rhône‑Alpes area of France. Along with offering monetary backing, CaLySeed will name on the companies of choose companions inside its community and determine specialists to assist analyze every begin‑ups’ positioning. Relying on how superior a start-up is, CaLySeed will then — particularly through the operational assist part — assemble and mobilize a workforce of specialists in a specific area, scientific self-discipline or skilled skillset to assist develop and implement related strategic roadmaps (e.g. round market entry, regulatory strategy, workforce construction and administration ethos or industrial manufacturing).
Since 2019, it has supplied direct monetary backing for 16 firms. with a mean ticket of €100k ($99.9K), amounting to a complete funding of €1.6 million ($1.5M). As a significant shareholder in Simba Santé 3 (Angelor group, France), it has additionally helped fund eight different start-ups within the healthcare sector.